Thaís Lohana Chanel Pereira Ribeiro

Thaís Lohana Chanel Pereira Ribeiro

Auto-generated profile, based on publicly available information

Thaís Lohana Chanel Pereira Ribeiro

Programa de Pós-Graduação em Ciências Aplicadas à Hematologia, Universidade do Estado do Amazonas (UEA), Manaus, Brazil

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Immunology Research
Verified
Journal Article
Open access
TRThaís Lohana Chanel Pereira Ribeiro
Thaís Lohana Chanel Pereira Ribeiro
GNGlenda Menezes Nogueira
Glenda Menezes Nogueira
MSMateus Souza-Barros
Mateus Souza-Barros
JMJúlia Santos Moraes
Júlia Santos Moraes
LSLarissa Silva Santos
Larissa Silva Santos
ACAllyson Guimarães Costa
Allyson Guimarães Costa
Human leukocyte antigen G (HLA‐G) is a nonclassical major histocompatibility complex class I molecule whose increased expression has been consistently associated with unfavorable prognosis in solid tumors and has emerged as a potential immunotherapeutic target in hematological malignancies. HLA‐G exhibits limited genetic diversity and generates multiple isoforms that play a critical role in immune tolerance, being physiologically expressed in immunoprivileged tissues and aberrantly upregulated in a variety of pathological conditions, including cancer. Accumulating evidence indicates that elevated HLA‐G expression contributes to tumor immune evasion and influences clinical outcomes in patients with leukemia, lymphoma, and multiple myeloma. Genetic variability within the HLA‐G gene, particularly polymorphisms located in regulatory regions such as the 14‐base pair insertion/deletion, has been associated with cancer susceptibility, disease progression, and adverse prognosis. In hematological malignancies, specific genotypes, including the homozygous deletion variant, have been linked to increased levels of membrane‐bound and soluble HLA‐G, correlating with impaired immune surveillance and reduced survival, particularly in chronic lymphocytic leukemia. Moreover, HLA‐G expressions may be modulated by inflammatory cytokines, such as interferon‐γ, further shaping the immunosuppressive tumor microenvironment. By functioning as a nonclassical immune checkpoint, HLA‐G represents a promising target for innovative immunotherapeutic strategies, including immune checkpoint blockade combinations and chimeric antigen receptor (CAR)‐T cell approaches directed against HLA‐G‐expressing malignant cells. In this review, we summarize current knowledge regarding HLA‐G expression, genetic polymorphisms, and immunoregulatory mechanisms in hematological malignancies, highlighting their clinical and translational implications. Improved understanding of HLA‐G‐mediated immune modulation may contribute to the development of novel prognostic biomarkers and therapeutic strategies aimed at restoring effective antitumor immunity.

14 April 2026 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
GNGlenda Menezes Nogueira
Glenda Menezes Nogueira
LGLuca Gabriel Marques Gonçalves
Luca Gabriel Marques Gonçalves
TPThaís Lohana Pereira-Ribeiro
Thaís Lohana Pereira-Ribeiro
LSLarissa Silva Santos
Larissa Silva Santos
FMFábio Magalhães-Gama
Fábio Magalhães-Gama
ACAllyson Guimarães Costa
Allyson Guimarães Costa
Background: Tumor suppressor genes play a central role in cancer development, and inherited genetic variation may influence both disease susceptibility and clinical outcomes. This study aimed to investigate the frequency and prognostic relevance of TP53 polymorphic variants in patients with acute lymphoblastic leukemia (ALL) from an admixed population in the Brazilian Amazon. Methods: A population-based case–control study was conducted including 193 patients diagnosed with ALL and 215 healthy controls. Germline TP53 polymorphisms rs1042522 and rs1642785 were genotyped, and allele and genotype frequencies were compared between groups. Associations with ALL susceptibility, relapse, and mortality were evaluated using multiple genetic models adjusted for age and sex. Combined genotype and haplotype analyses were performed, and overall survival was estimated using Kaplan-Meier curves and log-rank tests. Results: The CC genotype and the allele C were more frequent among ALL cases than controls. The allele C of rs1042522 ( p = 0.021) and rs1642785 ( p = 0.022) was associated with increased susceptibility to ALL. In addition, the allele C of rs1042522 was associated with a higher risk of relapse ( p = 0.016) and death ( p = 0.009). Protective effects against ALL were observed under the recessive model for rs1042522 ( p = 0.019) and the codominant model for rs1642785 ( p = 0.013). Both variants showed protective associations with mortality under the log-additive model. Combined genotype analysis revealed that the CG and GG genotypes of rs1042522 were associated with a reduced risk of relapse ( p < 0.001). Overall survival analysis showed reduced survival associated with the CC genotype, whereas improved survival was observed for the heterozygous CG genotype. Haplotype analysis indicated that the GG haplotype was associated with a reduced risk of ALL ( p = 0.007) and death ( p = 0.013). Conclusions: Our findings suggest that germline TP53 variants rs1042522 and rs1642785 modulate susceptibility and clinical outcomes in ALL, supporting their potential role as prognostic biomarkers. This study highlights the importance of population-based genomic investigations in underrepresented populations.